News – Page 967 – Endpoints News

Polaris’ Amir Nashat pulls together a $60M launch round to back the birth of a new biotech building a drug ...

7 years ago

Roche pulls another major piece out of the wobbly Alzheimer's jenga, shuttering crenezumab PhIIIs

7 years ago

Hit by trial setback, Aslan slashes staff and a study — hunkering down in wait for pivotal data

7 years ago

Aldeyra bags PhIII-ready eye drug in Helio buyout; Liquid biopsy maker OncoCyte shares skyrocket on validation data

7 years ago

Agenus touts blockchain tech to roll out new ‘digital security’ for its PD-1, but will it work?

7 years ago

Takeda claims PhIII success in dengue vaccine months after Dengvaxia implosion for rival Sanofi

7 years ago

As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

7 years ago

Pfizer and Lilly's tanezumab largely makes the efficacy cut in second PhIII study, but safety issues continue to ...

7 years ago

Voyager bags a 'transformational' $1.8B gene therapy pact with Neurocrine

7 years ago

Gottlieb lays out real world evidence priorities for 2019 with an eye on digital tools

7 years ago

Gates and Chinese private equity group cheer on Lyndra's PhII plans with $55M raise

7 years ago

Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech

7 years ago

Trevena forges plan to take once-rejected opioid across finish line, after 'productive' FDA meeting

7 years ago

The next 5 years: Higher R&D productivity is here to stay, emerging biotechs and new tech will have a big impact. But ...

7 years ago

Unfazed by Brexit blues, UK biotech trade group celebrates boisterous year of venture dollars with record £1.1B ...

7 years ago

The FDA is back in business; Allogene given the green signal to test lymphoma drug in humans

7 years ago

EMA says symbolic goodbye to London HQ as it sets up shop in Amsterdam

7 years ago

Disgraced at Vertex, Ian Smith’s career implosion ends with swift exile from biotech boards

7 years ago

Imbruvica regimen wins FDA approval as first non-chemotherapy treatment for untreated patients with common form of ...

7 years ago

Zai Lab nabs speedy China regulatory review for PARP drug Zejula

7 years ago

After securing quick OK for PNH patients, Alexion's Ultomiris succeeds in aHUS pivotal study

7 years ago

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

7 years ago

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

7 years ago

Novartis sounds alarm on unsustainable drug supply chain if no-deal Brexit becomes reality

7 years ago

First page Previous page 964 965 966967968 969 970 Next page Last page